Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

This is an open-label, multicenter, phase 1b study, which is designed to explore the safety, efficacy and PK of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) marketed in China, in combination with APG-2575 in treating R/R Ph+ALL children, and to preliminarily establish the recommended dose of olverembatinib and APG-2575 for children based on the above results.

Trial Details

NCT ID
NCT05495035
Phase
PHASE1
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Olverembatinib, APG-2575, Dexamethasone
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Jinan, Shandong, China|36.66833,116.99722
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Eligible patients must meet all of the following criteria:
  • Children under 18 years of age on the day of signing the informed consent form, and able to swallow the oral drugs during the study period.
  • Subjects who are diagnosed with Ph+ALL, and are resistant or intolerant to at least one TKI. If the subject has BCR-ABL1 T315I mutation, prior use …
  • Drug resistance includes disease recurrence and refractory disease. Relapse: Presence of blasts \> 5% in peripheral blood or bone marrow or presenc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →